Following the closure of Bacthera’s CDMO activities, Lallemand has acquired a broad range of state-of-the-art equipment to produce drug substances and drug products in anaerobic conditions, reinforcing its GMP Pharma production capabilities for next-generation strains. […]
COPENHAGEN, Denmark, Aug. 07, 2025 (GLOBE NEWSWIRE) — SNIPR Biome ApS (“SNIPR”), the company pioneering the development of microbial CRISPR-medicine, today announced the close of a EUR 35 million Series B raise with funding from […]
As interest in biotics1 and their wide range of health applications continues to grow, BioGaia is proud to announce the launch of a subsidiary company, BioGaia New Sciences AB, dedicated to exploring opportunities in microbiome […]
MaaT Pharma announces the signature of a license and commercial agreement with Clinigen, a global specialty pharmaceutical services group and a leading European player in hospital distribution and market access, to streamline the pathway for […]
Danone announces the acquisition of The Akkermansia Company (TAC), a Belgian company with nearly 20 years of history and science, specializing in biotics. In 2004, the team of Professor Willem M. de Vos at Wageningen University discovered, […]
32 Biosciences announced it has received $6 million in funding to support the continued development of its lead assets. The funding comes as the company prepares for a future Series A fundraise and advances toward key […]
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, announced the […]
Microba Life Sciences Limited (ASX: MAP) (“Microba”) a precision microbiome company, announces two significant developments: the release of new clinical utility results for its MetaPanel™ gastrointestinal pathogen test, and the signing of a strategic clinical partnership […]
PepsiCo, Inc. (NASDAQ: PEP) (“PepsiCo”) announced on Monday that it has entered into a definitive agreement to acquire poppi, a fast-growing prebiotic soda brand, for $1.95 billion, including $300 million of anticipated cash tax benefits for a […]
BiomX Inc. (NYSE American: PHGE, the “Company” or “BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it has entered into a securities purchase agreement […]
Owlstone Medical (“Owlstone”), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced a first closing of $27 million (circa £22 million) in its Series E financing round. The […]